Apellis Pharmaceuticals
Stock Forecast, Prediction & Price Target
Apellis Pharmaceuticals (APLS) stock Price Target by analysts
$57
Potential upside: 114.12%
Apellis Pharmaceuticals price prediction
What is Apellis Pharmaceuticals stock analysts` prediction?
Apellis Pharmaceuticals stock forecast: Based on 1 Wall Street analysts` predicted price targets for Apellis Pharmaceuticals in the last 3 months, the avarage price target is $57, with a high forecast of $NaN. The average price target represents a 114.12% change from the last price of $26.62.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Apellis Pharmaceuticals stock Price Target by analysts
Full breakdown of analysts given Apellis Pharmaceuticals price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Douglas Tsao H.C. Wainwright | 0% 0/2 | 11 months ago | $57 114.12% upside | $27.01 | StreetInsider | Previous targets (1) |
Colleen Kusy Robert W. Baird | 0% 0/3 | about 1 year ago | $92 245.60% upside | $31.75 | StreetInsider | Previous targets (2) |
Annabel Samimy Stifel Nicolaus | 50% 1/2 | about 1 year ago | $84 215.55% upside | $31.68 | StreetInsider | Previous targets (1) |
Graig Suvannavejh Mizuho Securities | 0% 0/3 | about 1 year ago | $39 46.50% upside | $36.73 | StreetInsider | Previous targets (2) |
Graig Suvannavejh Mizuho Securities | 0% 0/3 | about 1 year ago | $42 57.77% upside | $37.62 | StreetInsider | Previous targets (2) |
Colleen Kusy Robert W. Baird | 0% 0/3 | about 1 year ago | $96 260.63% upside | $37.66 | TheFly | Previous targets (2) |
Akash Tewari Jefferies | 0% 0/2 | about 1 year ago | $82 208.03% upside | $37.66 | StreetInsider | Previous targets (1) |
Douglas Tsao H.C. Wainwright | 0% 0/2 | about 1 year ago | $83 211.79% upside | $36 | TheFly | Previous targets (1) |
Colleen Kusy Robert W. Baird | 0% 0/3 | about 1 year ago | $86 223.06% upside | $38.88 | TheFly | Previous targets (2) |
Graig Suvannavejh Mizuho Securities | 0% 0/3 | about 1 year ago | $49 84.07% upside | $38.36 | StreetInsider | Previous targets (2) |
Derek Archila Wells Fargo | 50% 1/2 | over 1 year ago | $48 80.31% upside | $43.6 | TheFly | Previous targets (1) |
Akash Tewari Jefferies | 0% 0/2 | over 1 year ago | $80 200.52% upside | $68.16 | StreetInsider | Previous targets (1) |
Derek Archila Wells Fargo | 50% 1/2 | over 2 years ago | $58 117.88% upside | $51.71 | TheFly | Previous targets (1) |
Unknown J.P. Morgan | N/A | almost 3 years ago | $79 196.76% upside | $46.61 | Benzinga | N/A |
Unknown Wedbush | N/A | about 3 years ago | $67 151.69% upside | $67.07 | Benzinga | N/A |
Unknown Stifel Nicolaus | N/A | about 3 years ago | $65 144.17% upside | $65.38 | Benzinga | N/A |
Unknown Oppenheimer | N/A | about 3 years ago | $78 193.01% upside | $65.5 | Benzinga | N/A |
Unknown Credit Suisse | N/A | about 3 years ago | $52 95.34% upside | $63.58 | Benzinga | N/A |
Unknown Goldman Sachs | N/A | about 3 years ago | $102 283.17% upside | $62.33 | Benzinga | N/A |
Unknown Raymond James | N/A | about 3 years ago | $113 324.49% upside | $62.33 | Benzinga | N/A |
Unknown Citigroup | N/A | about 3 years ago | $86 223.06% upside | $52.06 | Benzinga | N/A |
Annabel Samimy Stifel Nicolaus | 50% 1/2 | over 3 years ago | $60 125.39% upside | $44.53 | Pulse 2.0 | Previous targets (1) |
Matthew Luchini BMO Capital | 100% 1/1 | almost 4 years ago | $69 159.20% upside | $37.34 | TipRanks Contributor | Previous targets (0) |
Laura Chico Wedbush | 100% 1/1 | almost 4 years ago | $28 5.18% upside | $37.34 | TheFly | Previous targets (0) |
Alethia Young Cantor Fitzgerald | 100% 1/1 | almost 4 years ago | $74 177.98% upside | $33.59 | TheFly | Previous targets (0) |
Chris Howerton Jefferies | 100% 1/1 | almost 4 years ago | $74 177.98% upside | $33.59 | TipRanks | Previous targets (0) |
Tiago Fauth Credit Suisse | 100% 1/1 | about 4 years ago | $38 42.74% upside | $34.93 | Benzinga | Previous targets (0) |
Phil Nadeau Cowen & Co. | 100% 1/1 | about 4 years ago | $70 162.96% upside | $67.8 | TheFly | Previous targets (0) |
Apellis Pharmaceuticals Financial Estimates
Apellis Pharmaceuticals Revenue Estimates
Apellis Pharmaceuticals EBITDA Estimates
Apellis Pharmaceuticals Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $66.56M N/A | $75.42M 13.30% | $396.59M 425.82% | Avg: $1.19B Low: $1.00B High: $1.44B avg. 200.79% | Avg: $1.65B Low: $1.43B High: $2.07B avg. 38.62% | Avg: $1.75B Low: $1.52B High: $2.20B avg. 6.23% | Avg: $1.95B Low: $1.70B High: $2.46B avg. 11.49% |
Net Income
% change YoY
| $-746.35M N/A | $-652.17M 12.61% | $-528.62M 18.94% | Avg: $100.90M Low: $-104.43M High: $485.39M avg. 119.08% | Avg: $385.45M Low: $3.56M High: $797.51M avg. 281.99% | Avg: $525.38M Low: $436.54M High: $700.78M avg. 36.30% | Avg: $640.46M Low: $532.16M High: $854.27M avg. 21.90% |
EBITDA
% change YoY
| $-533.00M N/A | $-584.5M -9.66% | $-495.21M 15.27% | Avg: $-676.51M Low: $-820.20M High: $-570.01M avg. -36.61% | Avg: $-937.78M Low: $-1.17B High: $-815.81M avg. -38.62% | Avg: $-996.25M Low: $-1.25B High: $-866.67M avg. -6.23% | Avg: $-1.11B Low: $-1.39B High: $-966.31M avg. -11.49% |
EPS
% change YoY
| -$8.84 N/A | -$6.15 30.42% | -$4.45 27.64% | Avg: $0.97 Low: -$0.88 High: $4.09 avg. 121.82% | Avg: $3.19 Low: $0.03 High: $6.72 avg. 228.78% | Avg: $4.43 Low: $3.68 High: $5.9 avg. 38.62% | Avg: $5.4 Low: $4.48 High: $7.2 avg. 21.90% |
Operating Expenses
% change YoY
| $597.64M N/A | $664.39M 11.17% | $855.20M 28.71% | Avg: $2.18B Low: $1.83B High: $2.64B avg. 155.13% | Avg: $3.02B Low: $2.63B High: $3.80B avg. 38.62% | Avg: $3.21B Low: $2.79B High: $4.03B avg. 6.23% | Avg: $3.58B Low: $3.11B High: $4.50B avg. 11.49% |
FAQ
What is Apellis Pharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 114.82% in 2025-2028.
We have gathered data from 13 analysts. Their low estimate is -104.43M, average is 100.90M and high is 485.39M.
What is Apellis Pharmaceuticals stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 64.28% in 2025-2028.
We have gathered data from 13 analysts. Their low revenue estimate is $1.00B, average is $1.19B and high is $1.44B.
What is Apellis Pharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 102.78% in 2025-2028.
We have gathered data from 13 analysts. Their low earnings per share estimate is -$0.88, average is $0.97 and high is $4.09.
What is the best performing analyst?
In the last twelve months 1 analysts have been covering Apellis Pharmaceuticals stock. The most successful analyst is Douglas Tsao.